NeoGenomics Inc (NEO)vsNatera Inc (NTRA)
NEO
NeoGenomics Inc
$10.90
-3.63%
HEALTHCARE · Cap: $1.37B
NTRA
Natera Inc
$215.31
-3.06%
HEALTHCARE · Cap: $30.37B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 235% more annual revenue ($2.50B vs $745.97M). NTRA leads profitability with a -9.1% profit margin vs -13.3%. NEO earns a higher WallStSmart Score of 51/100 (C-).
NEO
Buy51
out of 100
Grade: C-
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+77.8%
Fair Value
$51.46
Current Price
$10.90
$40.56 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 130.6% YoY
Reasonable price relative to book value
Revenue surging 38.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
ROE of -12.0% — below average capital efficiency
Trading at 17.3x book value
0.0% earnings growth
Weak financial health signals
ROE of -12.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NEO
The strongest argument for NEO centers on EPS Growth, Price/Book. Revenue growth of 11.1% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Debt/Equity. Revenue growth of 38.8% demonstrates continued momentum.
Bear Case : NEO
The primary concerns for NEO are PEG Ratio, Market Cap, Piotroski F-Score.
Bear Case : NTRA
The primary concerns for NTRA are Price/Book, EPS Growth, Piotroski F-Score.
Key Dynamics to Monitor
NEO profiles as a turnaround stock while NTRA is a hypergrowth play — different risk/reward profiles.
NEO carries more volatility with a beta of 1.80 — expect wider price swings.
NTRA is growing revenue faster at 38.8% — sustainability is the question.
NTRA generates stronger free cash flow (18M), providing more financial flexibility.
Bottom Line
NEO scores higher overall (51/100 vs 31/100) and 11.1% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
NeoGenomics Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company is headquartered in Fort Myers, Florida.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?